Company intelligence / Profile preview

ApniCure

Redwood City, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

ApniCure developed the Winx Sleep Therapy System, a home-use medical device using oral pressure therapy to treat obstructive sleep apnea. Clinical trials demonstrated significant improvements in apnea severity and patient adherence compared to standard CPAP treatment. The system received FDA clearance and was launched commercially in select U.S. markets around 2013, with positive published results from the ATLAST trial showing efficacy for mild, moderate, and severe OSA. There are no recent updates on further clinical development.

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Winx Sleep Therapy System

Commercial

Indications: Obstructive sleep apnea

Beyond the preview

Go deeper on ApniCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ApniCure.

Explore the full profile